127 related articles for article (PubMed ID: 28353142)
1. Analysis of Species-Selectivity of Human, Mouse and Rat Cytochrome P450 1A and 2B Subfamily Enzymes using Molecular Modeling, Docking and Dynamics Simulations.
Karthikeyan BS; Suvaithenamudhan S; Akbarsha MA; Parthasarathy S
Cell Biochem Biophys; 2018 Jun; 76(1-2):91-110. PubMed ID: 28353142
[TBL] [Abstract][Full Text] [Related]
2. Modelling species selectivity in rat and human cytochrome P450 2D enzymes.
Edmund GH; Lewis DF; Howlin BJ
PLoS One; 2013; 8(5):e63335. PubMed ID: 23691026
[TBL] [Abstract][Full Text] [Related]
3. Homology modeling and molecular dynamics of CYP1A1 and CYP2B1 to explore the metabolism of aryl derivatives by docking and experimental assays.
Rosales-Hernández MC; Mendieta-Wejebe JE; Trujillo-Ferrara JG; Correa-Basurto J
Eur J Med Chem; 2010 Nov; 45(11):4845-55. PubMed ID: 20813430
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences.
Lewis DF; Ito Y; Lake BG
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):679-84. PubMed ID: 20100069
[TBL] [Abstract][Full Text] [Related]
5. Ensemble modeling of substrate binding to cytochromes P450: analysis of catalytic differences between CYP1A orthologs.
Prasad JC; Goldstone JV; Camacho CJ; Vajda S; Stegeman JJ
Biochemistry; 2007 Mar; 46(10):2640-54. PubMed ID: 17300179
[TBL] [Abstract][Full Text] [Related]
6. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
[TBL] [Abstract][Full Text] [Related]
7. Investigation of ligand selectivity in CYP3A7 by molecular dynamics simulations.
Fan JR; Zheng QC; Cui YL; Li WK; Zhang HX
J Biomol Struct Dyn; 2015; 33(11):2360-7. PubMed ID: 26065334
[TBL] [Abstract][Full Text] [Related]
8. Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.
Sridhar J; Goyal N; Liu J; Foroozesh M
Molecules; 2017 Jul; 22(7):. PubMed ID: 28698457
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human and rat CYP1A1 enzyme by grapefruit juice compounds.
Santes-Palacios R; Romo-Mancillas A; Camacho-Carranza R; Espinosa-Aguirre JJ
Toxicol Lett; 2016 Sep; 258():267-275. PubMed ID: 27444380
[TBL] [Abstract][Full Text] [Related]
10. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
Bello M; Mendieta-Wejebe JE; Correa-Basurto J
Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
[TBL] [Abstract][Full Text] [Related]
11. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities.
Venhorst J; ter Laak AM; Commandeur JN; Funae Y; Hiroi T; Vermeulen NP
J Med Chem; 2003 Jan; 46(1):74-86. PubMed ID: 12502361
[TBL] [Abstract][Full Text] [Related]
12. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
13. A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1A.
Dai ZR; Ge GB; Feng L; Ning J; Hu LH; Jin Q; Wang DD; Lv X; Dou TY; Cui JN; Yang L
J Am Chem Soc; 2015 Nov; 137(45):14488-95. PubMed ID: 26488456
[TBL] [Abstract][Full Text] [Related]
14. Interactions of 2-phenyl-benzotriazole xenobiotic compounds with human Cytochrome P450-CYP1A1 by means of docking, molecular dynamics simulations and MM-GBSA calculations.
Mena-Ulecia K; MacLeod-Carey D
Comput Biol Chem; 2018 Jun; 74():253-262. PubMed ID: 29677600
[TBL] [Abstract][Full Text] [Related]
15. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
16. Insight into the effects of chiral isomers quinidine and quinine on CYP2D6 inhibition.
Ai C; Li Y; Wang Y; Chen Y; Yang L
Bioorg Med Chem Lett; 2009 Feb; 19(3):803-6. PubMed ID: 19103487
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma.
Bhattacharjee R; Devi A; Mishra S
J Mol Model; 2015 Oct; 21(10):272. PubMed ID: 26419972
[TBL] [Abstract][Full Text] [Related]
18. Characterization of chicken cytochrome P450 1A4 and 1A5: inter-paralog comparisons of substrate preference and inhibitor selectivity.
Yang J; An J; Li M; Hou X; Qiu X
Comp Biochem Physiol C Toxicol Pharmacol; 2013 May; 157(4):337-43. PubMed ID: 23474502
[TBL] [Abstract][Full Text] [Related]
19. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam.
Nims RW; Prough RA; Jones CR; Stockus DL; Dragnev KH; Thomas PE; Lubet RA
Drug Metab Dispos; 1997 Jun; 25(6):750-6. PubMed ID: 9193878
[TBL] [Abstract][Full Text] [Related]
20. Species difference in the induction of hepatic CYP1A subfamily enzymes, especially CYP1A2, by 2-methoxy-4-nitroaniline among rats, mice, and guinea pigs.
Souma S; Sekimoto M; Degawa M
Arch Toxicol; 2006 Nov; 80(11):739-47. PubMed ID: 16639589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
